Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q3 2024 · 10-Q
Revenue$165.00K$165.00K+17.0% vs Q3 2023 Net Income-$11.86M-$11.86MN/M vs Q3 2023 EPS Diluted-$0.25-$0.25N/M vs Q3 2023 Operating Income-$12,601,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$10,456,000N/M Margins · derivedOperating margin-7637.0%+36.8 pt vs Q3 2023
Net margin-7184.8%−283.4 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 7, 2024 · 38 d after period end